Paysign Q2 revenue beats estimates; outlook raised amid pharma program expansion

Paysign

05/08/2026 21:31

Overview
US fintech healthcare provider's Q2 revenue grew 48% yr/yr, beating analyst expectations
Net income for Q2 rose sharply yr/yr, driven by patient affordability and plasma business growth
Company raised full-year 2026 outlook for revenue and adjusted EBITDA

Outlook
Paysign raises 2026 revenue outlook to $114 mln–$117 mln from prior guidance
Company sees Q3 2026 revenue of $28.5 mln–$30 mln
Paysign expects to exit Q3 2026 with 165–170 active patient affordability programs and 561–563 plasma centers

Result Drivers
PHARMA PROGRAM EXPANSION - Co said pharma revenue rose 89% on addition of 51 net patient affordability programs and higher claims processing
PLASMA UTILIZATION - Plasma revenue rose 21% as existing centers saw higher average revenue and more loads per center, offsetting a decline in total centers
MARGIN EXPANSION - Gross and operating margins improved due to a greater mix of pharma revenue and expense discipline

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$28.30 mln
$26.35 mln (5 Analysts)
Q2 Net Income
 
$6.76 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the business support services peer group is "buy"
Wall Street's median 12-month price target for Paysign Inc is $11.00, about 18.5% above its August 4 closing price of $9.28
The stock recently traded at 33 times the next 12-month earnings vs. a P/E of 24 three months ago

Reuters Recommended Reads
Aug 5 - CVS Health Q2 revenue beats estimates, outlook raised
Aug 5 - Global Payments' Q2 adjusted revenue slightly misses estimates
Aug 4 - PACS Group reports Q2 revenue beat on higher occupancy, raises outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)